Shionogi & Co., Ltd.
Clinical trials sponsored by Shionogi & Co., Ltd., explained in plain language.
A Japanese pharmaceutical company focused on infectious diseases and pain management.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New RSV drug trial aims to protect vulnerable adults Results expected Dec 2026 (estimated)
- New drug combo targets breathing pauses in sleep apnea Results expected Dec 2026 (estimated)
- Can a new pill shorten COVID-19 symptoms? Results expected Jul 2027 (estimated)
- New pill could boost breathing in pompe disease – early trial underway Results expected Aug 2027 (estimated)
-
Hope for rare brain disorder: new drug trial targets Jordan's syndrome
Disease control OngoingThis study tests a drug called zatolmilast in 30 people aged 9 to 45 with Jordan's Syndrome, a rare genetic disorder affecting brain development. The goal is to see if the drug improves language and communication skills and is safe. Participants take the drug or a placebo for 24 …
Phase 2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets breathing pauses in sleep apnea
Symptom relief OngoingThis Phase 2A study tests three drugs—sivopixant, acetazolamide, and SASS-001—in 60 adults with sleep apnea that has a central component (where the brain fails to signal breathing). The goal is to see if these drugs can reduce the number of breathing pauses during sleep. Particip…
Phase 2 • Sponsor: Shionogi • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC